JP7026347B2 - アカンプロサートのスプリンクル製剤 - Google Patents

アカンプロサートのスプリンクル製剤 Download PDF

Info

Publication number
JP7026347B2
JP7026347B2 JP2017558372A JP2017558372A JP7026347B2 JP 7026347 B2 JP7026347 B2 JP 7026347B2 JP 2017558372 A JP2017558372 A JP 2017558372A JP 2017558372 A JP2017558372 A JP 2017558372A JP 7026347 B2 JP7026347 B2 JP 7026347B2
Authority
JP
Japan
Prior art keywords
disease
acamprosate
drug
sprinkles
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017558372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515506A5 (https=
JP2018515506A (ja
Inventor
ジョンズ，スティーブン，エル．
ペイー，ケニース，ジー．
ドニパルシ，バドゥリナス，アール．
ムニアンジャナッパ，シヴァラジ，ビー．
Original Assignee
コンフルーエンス ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンフルーエンス ファーマシューティカルズ，エルエルシー filed Critical コンフルーエンス ファーマシューティカルズ，エルエルシー
Publication of JP2018515506A publication Critical patent/JP2018515506A/ja
Publication of JP2018515506A5 publication Critical patent/JP2018515506A5/ja
Priority to JP2021103349A priority Critical patent/JP2021155434A/ja
Application granted granted Critical
Publication of JP7026347B2 publication Critical patent/JP7026347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2017558372A 2015-05-04 2016-05-04 アカンプロサートのスプリンクル製剤 Active JP7026347B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021103349A JP2021155434A (ja) 2015-05-04 2021-06-22 アカンプロサートのスプリンクル製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562156842P 2015-05-04 2015-05-04
US62/156,842 2015-05-04
US201562260161P 2015-11-25 2015-11-25
US62/260,161 2015-11-25
PCT/US2016/030725 WO2016179252A1 (en) 2015-05-04 2016-05-04 Sprinkle formulations of acamprosate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103349A Division JP2021155434A (ja) 2015-05-04 2021-06-22 アカンプロサートのスプリンクル製剤

Publications (3)

Publication Number Publication Date
JP2018515506A JP2018515506A (ja) 2018-06-14
JP2018515506A5 JP2018515506A5 (https=) 2019-06-06
JP7026347B2 true JP7026347B2 (ja) 2022-02-28

Family

ID=57217823

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017558372A Active JP7026347B2 (ja) 2015-05-04 2016-05-04 アカンプロサートのスプリンクル製剤
JP2021103349A Pending JP2021155434A (ja) 2015-05-04 2021-06-22 アカンプロサートのスプリンクル製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021103349A Pending JP2021155434A (ja) 2015-05-04 2021-06-22 アカンプロサートのスプリンクル製剤

Country Status (10)

Country Link
US (1) US10709668B2 (https=)
EP (1) EP3291800A4 (https=)
JP (2) JP7026347B2 (https=)
KR (1) KR102790656B1 (https=)
AU (1) AU2016258624B2 (https=)
HK (1) HK1252003A1 (https=)
IL (1) IL255343B2 (https=)
SG (1) SG11201708393UA (https=)
WO (1) WO2016179252A1 (https=)
ZA (1) ZA201708037B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357469B2 (en) 2015-02-18 2019-07-23 Aston University Diagnostic assay and treatment for preeclampsia
SG11201708393UA (en) 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate
HK1255584A1 (zh) * 2015-08-04 2019-08-23 Confluence Pharmaceuticals, Llc 使用阿坎酸及d-环丝胺酸的联合疗法
IL270654B2 (en) * 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
ES2938609T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
EP4213817A1 (en) * 2020-09-21 2023-07-26 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
EP4406479A4 (en) 2021-09-24 2025-05-07 Sumitomo Bakelite Co.Ltd. Brain wave detection electrode, brain wave measurement device, and brain wave measurement method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077878A1 (en) 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
JP2014508812A (ja) 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE1073432T1 (de) 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
JP2010532331A (ja) 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
CA2781830C (en) 2009-02-12 2018-03-27 Indiana University Research & Technology Corporation Materials and methods for treating developmental disorders including comorbid and idiopathic autism
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
TR201809351T4 (tr) 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
JP5893135B2 (ja) 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
SG11201708393UA (en) 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077878A1 (en) 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
JP2014508812A (ja) 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Also Published As

Publication number Publication date
US10709668B2 (en) 2020-07-14
EP3291800A1 (en) 2018-03-14
US20190046458A1 (en) 2019-02-14
KR102790656B1 (ko) 2025-04-02
JP2018515506A (ja) 2018-06-14
AU2016258624B2 (en) 2021-07-29
EP3291800A4 (en) 2018-09-26
SG11201708393UA (en) 2017-11-29
IL255343B2 (en) 2024-10-01
ZA201708037B (en) 2020-03-25
IL255343A0 (en) 2017-12-31
HK1252003A1 (zh) 2019-05-10
KR20170142180A (ko) 2017-12-27
WO2016179252A1 (en) 2016-11-10
JP2021155434A (ja) 2021-10-07
IL255343B1 (en) 2024-06-01
AU2016258624A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
JP7026347B2 (ja) アカンプロサートのスプリンクル製剤
ES2306535T3 (es) Formulaciones orales de metilfenidato de liberacion controlada/modificada.
US20030170181A1 (en) Method for preventing abuse of methylphenidate
US20170042839A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2021038224A (ja) 特に注意欠陥障害の治療のための方法および組成物
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
JP2021518429A (ja) 腸溶性ソフトゲルカプセル剤
TW202128135A (zh) 在較高pH環境中之緩釋軟膠囊
JP7499539B2 (ja) ホモタウリンおよびその塩の製剤
KR20200053570A (ko) 기면증의 치료에서 가복사돌의 사용
HK1207563A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
CA3062834C (en) Formulations of homotaurines and salts thereof
WO2005067909A1 (en) Combination therapy with mecamylamine for the treatment of mood disorders
US9339475B2 (en) Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
WO1985000516A1 (en) Sustained release method and product
EP4456873A1 (en) Oral films of antipruritic drugs
Jagdale et al. Superdisintegrant selection for tramadol dispersible tablets

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210622

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210713

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210824

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220203

R150 Certificate of patent or registration of utility model

Ref document number: 7026347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250